Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma

Background: The performance of immune checkpoint inhibitor (ICI) monotherapy was proved to be disappointing in pancreatic ductal adenocarcinoma (PDAC). Increasing evidence has shown the promising efficacy of ICIs combined with systemic therapy in the first-line treatment in solid tumors. Case presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Shui, Lin, Cheng, Ke, Li, Xiaofen, Shui, Pixian, Li, Shuangshuang, Peng, Yang, Li, Jian, Guo, Fengzhu, Yi, Cheng, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318868/
https://www.ncbi.nlm.nih.gov/pubmed/32636837
http://dx.doi.org/10.3389/fimmu.2020.01127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318868/
https://www.ncbi.nlm.nih.gov/pubmed/32636837
http://dx.doi.org/10.3389/fimmu.2020.01127

Ejemplares similares